About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Houston | 822 Studies

Clinical Trials LymphomaHouston

Lymphoma Clinical Trials in Houston

Find 822 clinical trials for lymphoma near Houston, Texas. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Houston

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-20 of 822 trials

RecruitingIDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersThis is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without…NCT06119685·Los Angeles, California and 11 others RecruitingA Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaThis study is researching an experimental drug called odronextamab, referred to as study drug.NCT06091254·Tucson, Arizona and 189 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

TerminatedCombination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's LymphomaPrimary Objectives: 1. To evaluate the response rate for patients with T-cell Non-Hodgkin's Lymphoma (NHL)receiving the combination of vorinostat and bortezomib 2.NCT00810576·Houston, Texas

CompletedDevelopment of Strategies to Increase Enrollment in Clinical Trials for Children With CancerRATIONALE: Taking part in a clinical trial may help children with cancer receive more effective treatment.NCT00002485·Sacramento, California and 30 others

CompletedStudy of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaThis phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma.NCT01258998·Houston, Texas

CompletedPhase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapyPhase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete…NCT00790036·Chandler, Arizona and 201 others

TerminatedA Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe…NCT03138499·Duarte, California and 21 others

TerminatedStudy of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory…NCT01685021·Columbus, Ohio and 2 others

CompletedAlisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasThis phase I trial studies the side effects and best dose of alisertib and romidepsin in treating patients with B-cell or T-cell lymphomas that have returned after a period of…NCT01897012·Houston, Texas

Active not recruitingA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).NCT05578976·Tucson, Arizona and 330 others

TerminatedSingle Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing TherapyThis was a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in…NCT01200589·Anchorage, Alaska and 154 others

CompletedStudy Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell LymphomaStudy of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed \& Refractory Mantle Cell LymphomaNCT00038623·Houston, Texas

TerminatedVOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)The purpose of the study was to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients…NCT04702425·Houston, Texas and 8 others

CompletedA Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic MalignanciesThe purpose of this study is to evaluate a multi-dose regimen of SGN-30, a novel chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic…NCT00051597·Birmingham, Alabama and 9 others

Active not recruitingStudy of Pembrolizumab (MK-3475) in Combination With RomidepsinThis phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how well they work in treating participants with peripheral T-cell lymphoma that has come…NCT03278782·Houston, Texas

CompletedStudy to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic LeukemiaThe primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target…NCT01088048·Huntsville, Alabama and 10 others

Active not recruitingStudy of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsThis is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who…NCT03876769·Birmingham, Alabama and 42 others

TerminatedSafety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCLThe purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and…NCT02361346·Tucson, Arizona and 40 others

RecruitingA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaThis study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy.NCT06091865·Scottsdale, Arizona and 189 others

RecruitingPhase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell NeoplasmsThe goal of this clinical research study is to find the highest tolerable dose of JV-394 (a type of autologous CAR-T cell therapy) that can be given to patients who have T/NK cell…NCT07382817·Houston, Texas

Page 1 of 42Next

Other Conditions in Houston

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia